Hims & Hers Health y Novo Nordisk ponen fin a demanda por fármacos para bajar de peso y colaboran

Por MICHELLE CHAPMANNovo Nordisk está desestimando su demanda por infracción de patente contra la empresa de telesalud Hims & Hers, ya que ambas compañías han llegado a un

Hims & Hers Shares Double on Report of Wegovy Tie-Up

Stock skyrocketed premarket following a media report that the maker of Wegovy plans to sell the weight-loss drug on the Hims & Hers platform.

Novo Nordisk Targets Obesity Edges With Irish Spend And Hims Alliance

Novo Nordisk (CPSE:NOVO B) is committing €432 million to expand its oral GLP-1 manufacturing facility in Ireland, aimed at supporting future products and supply outside the US. The company has settled its dispute with Hims and entered a partnership that allows branded obesity drugs to be offered through the Hims telehealth platform.
STAT

Novo Nordisk is warned by the FDA for failing to report potential side effects tied to GLP-1 drugs

Novo Nordisk received a warning from the Food and Drug Administration for failing to report suspected incidents of side effects caused by its medicines, a step that is required by federal law. In a March 5 warning letter,